The rapidly increasing prevalence of metabolic disorders associated with nonalcoholic fatty liver disease (NAFLD) warrants further study of the underlying mechanisms to identify key regulators as targets for the development of therapeutic interventions. Caspase recruitment domain protein 6 (Card6), as a member of the CARD family that regulates cell death and immunity, may potentially control this process. Indeed, Card6 down-regulation was found to be closely associated with the fatty livers observed in NAFLD patients, obese mice, and a palmitate-treated hepatocyte model. Gain-of-function and loss-of-function Card6 mouse models demonstrated that Card6 protected mice from insulin resistance, hepatic steatosis, and inflammatory responses upon high-fat diet administration. Mechanistically, Card6 interacted with and inhibited apoptosis signal-regulating kinase 1 (Ask1) and its subsequent downstream c-Jun N-terminal kinase/p38 signaling. Furthermore, Ask1 was sufficient to mediate Card6 function, and the interaction between Ask1 and Card6 was absolutely required for Card6 function in vivo. Adenovirus-mediated Card6 overexpression in the liver effectively ameliorated insulin resistance and hepatic steatosis in ob/ob mice. Therefore, we identified Card6 as an important negative regulator in NAFLD. 
N onalcoholic fatty liver disease (NAFLD), which is characterized by excessive hepatic fat accumulation and associated with insulin resistance, is becoming the leading cause of chronic liver diseases worldwide.
(1-3) Nearly 30% of NAFLD patients progress to nonalcoholic steatohepatitis (NASH), which is characterized by chronic liver injury, inflammation, and fibrosis in addition to hepatic steatosis. (4, 5) NAFLD and NASH may ultimately progress to cirrhosis and eventually hepatocellular carcinoma, which can only be resolved by liver transplantation. (6) Although the presence of multiple features of metabolic syndrome, type 2 diabetes mellitus, obesity, and increasing age are closely associated with NAFLD, the underlying mechanisms of NAFLD have not been adequately elucidated. (7) Despite the emergence of several treatment modalities during the past decade, (8) (9) (10) there is still no approved drug therapy for NAFLD. Therefore, it is important to identify new potential therapeutic targets and strategies for NAFLD treatment.
Caspase recruitment domain protein 6 (Card6) is a typical member of the CARD family, which is known to form large complexes through the CARD domain to regulate apoptosis and inflammation. (11) Indeed, Card6 interacts with receptor interacting serine/threonine protein kinase 2 (RIPK2), a member of the CARD family, to activate nuclear factor kappa B (NF-κB) signaling. (12, 13) Card6 also shares structural features with the interferon-inducible guanosine triphosphatase (GTPase) family and can be induced by interferon in bone marrow-derived macrophages, B cells, T cells, and splenocytes. (14) Other studies also implicate Card6 involvement in immune diseases and cancers, including psoriasis (15) and gastric, colorectal, and esophageal cancers. (16) Unexpectedly, Card6-deficient mice do not exhibit any abnormalities in the innate immune response. (14) However, Card6-deficient mice show worse cardiac hypertrophy induced by pressure overload. (17) These observations suggest a stress-dependent function of Card6 under pathological conditions. Considering the potential role of Card6 in NF-κB signaling, we speculated that Card6 may play a role in NAFLD.
In this study, we observed a close association between reduced Card6 and NAFLD that was confirmed in high-fat diet (HFD)-induced NAFLD mice and in genetically obese mice. We further determined the function of Card6 in NAFLD by using gain-of-function and loss-of-function mouse models. We showed that Card6 protects against NAFLD by interacting with and suppressing activation of apoptosis signal-regulating kinase 1 (Ask1) and its subsequent p38/c-Jun N-terminal kinase ( Jnk) signaling. Card6 overexpression reversed HFD-induced and genetic NAFLD. Thus, we identified Card6 as a negative regulator of NAFLD.
Materials and Methods

HuMaN lIVeR SaMpleS
Human steatotic liver samples were collected from patients with NAFLD undergoing liver biopsy, as described. (18) Patients with liver steatosis due to excessive alcohol consumption, drug/toxin use, or viral infection were excluded from the study. Control samples were obtained from normal liver donors who had undergone liver resection for a liver hemangioma or hepatic cyst. Written informed consent was obtained from each patient or family member of the liver donors. Hepatic steatosis was independently diagnosed by two pathologists using standard criteria. (19) All procedures involving human samples were approved by the Zhongnan Hospital of Wuhan University Review Board, Wuhan, China, and conducted in compliance with the principles outlined in the Declaration of Helsinki.
NaFlD MouSe MoDel
Male mice (8-10 weeks old) were housed in a temperature-controlled environment (23 ± 2°C) with a 12-hour light-dark cycle and fed the HFD (18.1% protein, 61.6% fat, and 20.3% carbohydrates; D12492; Research Diets, New Brunswick, NJ) for 24 weeks as described. (20) Mice that were fed a normal chow (NC) diet (18.3% protein, 10.2% fat, and 71.5% carbohydrates; D12450B; Research Diets) served as controls. ob/ob mice were also used as a genetic NAFLD mouse model.
MICe
Card6-floxed mice were generated using clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated 9 (Cas9) methods. Two single-guide RNAs (sg1 and sg2) targeting the Card6 introns 3 and 3′ noncoding regions were designed. The donor vector contained exon 4 flanked by two loxP sites and two homology arms as templates for homologous recombination (Supporting Fig. S1 ). Card6-floxed mice were consequently generated from zygotes that were injected with an mRNA encoding the nuclease Cas9, the single-guide RNAs, and the donor vector. Primers marked as P1, P2, P3, P4, P5, and P6 were used for the PCR-based genotype (Supporting Table S1 ). Hepatocyte-specific Card6-knockout (Card6-HKO) mice were generated by mating Card6 flox/flox (Card6-Flox) mice with albumin-Cre mice ( Jackson Laboratory, Bar Harbor, ME). To obtain transgenic mice with hepatocyte-specific expression (HTG), complementary DNAs (cDNAs) of Card6, mutant Card6 (Card6-M), constitutively active Ask1 (caAsk1), and dominant negative Ask1 (dnAsk1) were cloned downstream of the albumin (Alb) promoter for microinjection, as described. (21) caAsk1-HTG mice were further crossed with Card6-HTG mice, and dnAsk1-HTG mice were mated with Card6-HKO to create caAsk1-HTG/Card6-HTG mice and dnAsk1-HTG/Card6-HKO, respectively. Male ob/ob mice were purchased from the Model Animal Research Center of Nanjing University (Nanjing, China 
MetaBolIC aSSayS
Mouse metabolic assays were performed as reported. (22) Briefly, fasting blood glucose and fasting serum insulin levels were examined in mice every 4 weeks using a glucometer (One Touch Ultra Easy; Life Scan, Wayne, PA) and enzyme-linked immunosorbent assay (ELISA; Millipore, Billerica, MA), respectively. The mice were fasted for 6 hours before the tests were performed. The homeostatic model assessment of insulin resistance (HOMA-IR) was calculated using the homeostasis model as follows: [fasting blood glucose (mmol/L) × fasting serum insulin (mIU/L)]/22.5.
To perform glucose tolerance tests (GTTs) and insulin tolerance tests (ITTs), mice were intraperitoneally injected with 1 g/kg glucose (Sigma-Aldrich, St. Louis, MO) and 0.75 U/kg insulin (Novolin R; Novo Nordisk Co., Bagsvaerd, Denmark), respectively. Blood glucose levels were measured at 0, 15, 30, 60, and 120 minutes after injection. Areas under the curve were calculated to reflect glucose tolerance and insulin tolerance levels.
HIStologICal aNalySIS
Periodic acid-Schiff (PAS) staining was performed using paraffin-prepared liver sections to determine the glycogen content of the tissues. Liver sections were embedded in paraffin and stained with hematoxylin and eosin (H&E) to visualize adipocytes and inflammatory cells in the tissues. Oil red O staining of frozen liver sections was performed to assess lipid droplet accumulation. Images were acquired with a light microscope (Olympus, Tokyo, Japan).
MouSe HepatIC lIpID aND SeRuM CytoKINe aNalySeS
Commercial kits were used to measure the triglyceride (TG), total cholesterol (TC), and nonesterified fatty acid (NEFA) contents in the liver according to the manufacturer's instructions (290-63701 for TG, 294-65801 for TC, 294-63601 for NEFA; Wako, Tokyo, Japan). Serum concentrations of cytokines were determined using ELISA kits (PMTA00B for tumor necrosis factor alpha [Tnf-α] 
lIVeR FuNCtIoN teSt
Liver function was evaluated in mice by determining the activities of alanine transaminase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) in the serum using an ADVIA 2400 Chemistry System analyzer (Siemens, Tarrytown, NY) according to the manufacturer's instructions.
ISolatIoN, CultuRe, aND tReatMeNt oF pRIMaRy HepatoCyteS
Primary hepatocytes from 6-to 8-week-old mice were isolated by liver perfusion as described. (20) Briefly, mice were anesthetized with pentobarbital sodium (90 mg/kg). A total of 45 mL of Liver Perfusion Medium (Life Technologies, Carlsbad, CA; 17701-038) was perfused through the portal vein, followed by perfusion of Liver Digest Medium (Life Technologies; 17703-034) for 5 minutes at a rate of 2 mL/minute. After digestion, the liver was excised, minced, and filtered through a steel mesh (100 μm; Life Technologies). Primary hepatocytes were separated by centrifugation at 50g for 5 minutes and purified on 50% Percoll solution (17-0891-01; GE Healthcare Life Sciences, Little Chalfont, UK). The obtained hepatocytes were resuspended in Dulbecco's modified Eagle's medium. Trypan blue exclusion assays indicated that cell viability was >95%. Hepatocytes were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin in a 5% CO 2 /water-saturated incubator at 37°C. Palmitate (0.25 mM; Sigma-Aldrich) was added to the medium for 24 hours to establish the in vitro model of lipid accumulation in hepatocytes.
aDeNoVIRuS-MeDIateD geNe oVeReXpReSSIoN aND KNoCKDoWN
For overexpression, Ask1 and Card6 cDNAs were subcloned into a replication-defective adenoviral (Ad) vector under the control of the cytomegalovirus promoter. For knockdown, short hairpin RNAs were subcloned into a replication-defective Ad vector under the control of the U6 promoter. Ad green fluorescent protein (AdGFP) and scramble short hairpin RNA were used as controls, respectively. Ad preparation and infection into cells and mice were performed as described. (20) Cells were infected with Ads in diluted medium at a multiplicity of infection of 50. Wild-type (WT) mice were injected with Ad (5 × 10 9 pfu) in the jugular vein.
QuaNtItatIVe Rt-pCR
Total RNA was extracted from tissues or cells using TRIzol reagent (15596-026; Invitrogen) and then quantified using a Nanodrop 2000 spectrophotometer. cDNA was generated from total RNA using a Transcriptor First-Strand cDNA Synthesis Kit (catalog no. 04896866001; Roche) according to the manufacturer's instructions. Quantitative RT-PCR was performed using SYBR Green PCR Master Mix (catalog no. 04887352001; Roche). The mRNA expression levels of inflammation-related genes were normalized to those of the β-actin gene. The primer pairs used in this study are listed in Supporting Table S2 .
plaSMID CoNStRuCtS
To generate psi-Flag-Card6 and pcDNA5-FlagAsk1, the sequences encoding the full-length Card6 and Ask1 genes were cloned into psi-Flag and pcD-NA5-Flag vectors, respectively. Plasmids encoding pcDNA5-hemagglutinin (HA)-glutathione S-transferase (GST)-Card6 and pcDNA5-HA-GSTAsk1 were obtained by cloning the indicated cDNA of Card6 and Ask1 into pcDNA5-HA-GST vectors, respectively. Card6 truncations (residues 1-280, 281-480, 481-949, and 950-1175) were obtained by PCR amplification of pcDNA3.1-HA-Card6 using the indicated primer pairs. Plasmid encoding truncated pcDNA5-HA-Ask1 was generated as described. (23) The primers used to generate these constructs are listed in Supporting Table S3 .
Cell lINeS
The cell lines used in this study, including HEK293T and the normal human hepatocyte cell line L-02, were purchased from the Type Culture Collection of the Chinese Academy of Sciences, Shanghai, China. Mycoplasma contamination was assessed, and the results were negative. Both cell lines were authenticated in-house by short tandem repeat DNA profiling before the study.
IMMuNopReCIpItatIoN aND WeSteRN Blot
Immunoprecipitation was performed as described. (23) Briefly, after transfection with the indicated plasmids for 24 hours, HEK293T cells were lysed in ice-cold immunoprecipitation buffer (20 mM trishydroxymethylaminomethane-HCl, pH 7.4, 150 mM NaCl, 1 mM ethylene diamine tetraacetic acid, and 0.5% Nonidet P40) supplemented with protease inhibitor cocktail (catalog no. 04693132001; Roche). Next, cell lysates were incubated with Protein A/G-agarose beads (catalog nos. 11719394001 and 11719386001; Roche) and the indicated antibody on a rocking platform (overnight at 4°C) according to the manufacturer's recommendations. Finally, cell lysates and immunoprecipitations were used for sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) and western blotting as described. (20) A ChemiDoc MP Imaging System (Bio-Rad, Hercules, CA) was used to detect the signal. Protein expression levels were quantified with Image Lab software and normalized to the housekeeping gene β-actin. The antibodies used in this study are listed in Supporting Table S4 .
pull-DoWN aSSay
Plasmids expressing HA-GST, HA-GST-Ask1, HA-GST-Card6, Flag-Card6, and Flag-Ask1 were used for transfection into HEK293T cells. A pulldown assay was performed as described. (23) The isolated proteins were resolved by SDS-PAGE and then analyzed by western blotting using the indicated antibodies.
StatIStICal aNalySIS
All statistical analyses were performed using SPSS software (version 19.0), and all data are expressed as the mean ± standard deviation. For data with a normal distribution and homogeneity of variance, two-tailed Student t tests were used to evaluate significant differences between two groups, and a one-way analysis of variance was performed for comparisons among more than two groups using a Bonferroni analysis. P < 0.05 was considered significant. No statistical method was used to predetermine the sample size. No data were excluded. Randomization and blinding strategies were used whenever possible. Animal cohort sizes were determined on the basis of similar previous studies.
( [21] [22] [23] [24] 
Results
HepatIC Card6 DoWNRegulatIoN IS aSSoCIateD WItH HepatIC SteatoSIS
We examined CARD6 expression in liver biopsy samples from NAFLD patients and normal donors to explore its possible involvement in NAFLD. CARD6 expression at both the protein and the mRNA levels was markedly reduced in NAFLD livers (Fig. 1A,B) . Moreover, gradually decreased Card6 was observed in the livers of mice from 8 to 24 weeks after HFD treatment (Fig. 1C,D) . Reduced Card6 was confirmed in primary mouse hepatocytes treated with palmitate in a time-dependent manner ( Fig. 1E ) and in the livers of genetically (ob/ob) obese mice from 2 to 12 weeks (Fig. 1F) . All of these data indicate that Card6 reduction in the liver is associated with hepatic steatosis and that Card6 may be involved in NAFLD.
Card6 aMelIoRateS HFD-INDuCeD oBeSIty, HepatIC SteatoSIS, INSulIN ReSIStaNCe, INFlaMMatIoN, aND lIVeR FuNCtIoN DaMage
We generated Card6-HKO mice (Supporting Fig.  S2A ) and challenged these mice with an HFD or an NC diet for 24 weeks. As expected, HFD treatment significantly increased the body weights of both Flox HFD and Card6-HKO HFD mice compared with those of Flox NC and Card6-HKO NC mice, respectively (Supporting Fig. S2B ). Noticeably, Card6-HKO HFD mice gained more weight than Flox HFD mice, while no significant difference was observed between Flox NC and Card6-HKO NC mice (Supporting Fig.  S2B ). Insulin resistance is closely associated with obesity. Indeed, Card6-HKO HFD mice exhibited higher levels of fasting blood glucose and fasting insulin levels and higher HOMA-IR values than Flox HFD mice ( Fig. 2A-C) . Furthermore, Card6 deficiency negatively affected glucose tolerance and insulin sensitivity according to the GTTs and ITTs and reduced gluconeogenesis as revealed by PAS staining ( Fig. 2D-F; Supporting Fig. S2C,D) . Consistently, insulin signaling was impaired in the livers of Card6-HKO mice as reflected by decreased phosphorylation levels of insulin receptor substrate 1 (Irs1), Akt, and glycogen synthase kinase 3 beta (Gsk3β) compared to those in Flox mice (Fig. 2G) . In contrast, we used Card6 transgenic mice with specific overexpression of Card6 in hepatocytes (Card6-HTG) (Supporting Fig. S2E ) and observed the opposite phenotypes. The Card6-HTG mice showed reduced body weight, decreased levels of fasting blood glucose and insulin in the serum, improved insulin sensitivity and glucose tolerance, and enhanced gluconeogenesis and insulin signaling compared with WT mice (Fig. 2H-N ; Supporting Fig. S2F-H) .
Long-term HFD intake causes excessive lipid accumulation in the liver. We noticed that Card6 deficiency exacerbated hepatic steatosis. The Card6-HKO mice exhibited increased liver weights and liver-to-body weight ratios (Fig. 3A) and elevated levels of TGs, TC, and NEFAs in the liver (Fig. 3B) . Histological analysis (H&E and oil red O staining) revealed greater lipid accumulation in the livers of Card6-HKO mice than in the livers of Flox mice ( Fig. 3C) . Accordingly, fatty acid synthesis-related genes (Hmgcr, Fabp1, Fas, and Cd36) were up-regulated, whereas Ppara and Cyp7a1, which promote fatty acid oxidization, were reduced (Fig. 3D) . Moreover, Card6 deficiency led to more severe inflammation compared with that in Flox mice, as indicated by increased proinflammatory factors (Tnf-α, Il-1β, Il-4, Il-6, Il-2, and Mcp1), decreased anti-inflammatory factor Il-10 in the serum, and greater activation of p65 signaling in livers (Fig. 3E-F) . Finally, the Card6-HKO mice showed worse liver dysfunction with higher ALT, AST, and ALP activities in the serum than Flox mice (Fig. 3G) . In contrast to Card6 deficiency, Card6 overexpression in hepatocytes reversed these phenotypes, ameliorated hepatic steatosis, and reduced inflammation and liver damage (Fig. 3H-N) . Taken together, these observations suggest that Card6 protects against HFD-induced insulin resistance, hepatic steatosis, the inflammatory response, and liver damage.
Card6 SuppReSSeS ask1 pHoSpHoRylatIoN aND SuBSeQueNt DoWNStReaM p38/Jnk SIgNalINg IN HepatIC SteatoSIS
Mitogen-activated protein kinase (MAPK) pathways are activated and play critical roles in the pathogenesis of NAFLD. As expected, HFD induced the activation of extracellular signal-regulated kinase (Erk), Jnk1/2, and p38 (Fig. 4A) . Notably, Card6 deficiency enhanced Jnk1/2 and p38 phosphorylation, whereas sustained Card6 expression in Card6-HTG hepatocytes abrogated HFD-induced activation of Jnk1/2 and p38 (Fig. 4A) . In both settings, Erk phosphorylation was not significantly altered. Ask1 and transforming growth factor beta-activated kinase 1 (Tak1) are two key upstream kinases that activate MAPKs in various pathophysiological processes. (25) The HFD challenge increased Ask1 and Tak1 activation. Ask1 phosphorylation was further increased by Card6 deficiency; but it was suppressed by Card6 overexpression, and Tak1 phosphorylation was not affected (Fig. 4B) .
We further investigated how Card6 might suppress Ask1 phosphorylation. We found that Card6 was efficiently coimmunoprecipitated with Ask1 in primary hepatocytes and vice versa (Fig. 4C) , suggesting an interaction between Card6 and Ask1. In fact, a GST pull-down assay further verified a direct interaction between Card6 and Ask1 (Fig. 4D) . Mapping with serial truncation forms of Card6 and Ask1 demonstrated that the Card6 (281-480) fragment interacted with the Ask1 (679-936) fragment (Fig. 4E ).
ask1 MeDIateS tHe eFFeCt oF Card6 IN NaFlD
Given that Card6 interacted with Ask1 and inhibited Ask1 phosphorylation, we explored whether Ask1 mediated Card6 function in vitro and in vivo. In palmitate-treated, Card6-deficient hepatocytes, the enhanced activation of p38 and Jnk1/2 was normalized by Ask1 knockdown, whereas Ask1 overexpression efficiently restored p38 and Jnk1/2 phosphorylation in palmitate-treated Card6-HTG hepatocytes (Supporting Fig. S3A ). These observations indicate that Card6 negatively regulates p38/ Jnk1/2 by inhibiting Ask1 phosphorylation in hepatic steatosis. Furthermore, we generated two transgenic mouse lines with liver-specific expression of a dominant negative form of Ask1 (dnAsk1-HTG) or a constitutively active form of Ask1 (caAsk1-HTG). First, we crossed dnAsk1-HTG mice with Card6-HKO mice to obtain dnAsk1-HTG/Card6-HKO mice (Fig. 5A) . As expected, Card6-HKO mice showed a worse phenotype than Flox mice. Notably, dnAsk1 overexpression sufficiently reversed all phenotypes in dnAsk1-HTG/Card6-HKO mice. dnAsk1 ameliorated body and liver weights; fasting blood insulin and glucose; HOMA-IR, GTT, and ITT results; lipid accumulation; and liver dysfunction in dnAsk1-HTG/ Card6-HKO mice compared with Card6-HKO mice (Fig. 5B-K) . These observations suggest that Ask1 activation is required for the effect of Card6 deficiency. Second, we created double transgenic caAsk1-HTG/ Card6-HTG mice (Fig. 6A) . Again, sustained Card6 expression showed a protective effect. However, caAsk1 efficiently counteracted the protective effect and worsened the phenotype. Notably, caAsk1 significantly aggravated body and liver weights; fasting blood insulin and glucose; HOMA-IR, GTT, and ITT results; lipid accumulation; inflammation; and liver dysfunction in dnAsk1-HTG/Card6-HKO mice compared with Card6-HTG mice (Fig. 6B-L ). These results demonstrate that Ask1 is a major downstream effector of Card6. Altogether, these findings indicate that Card6 exerts its function in NAFLD by modulating Ask1.
INteRaCtIoN WItH ask1 IS ReQuIReD FoR Card6 FuNCtIoN IN NaFlD IN VIVO
We created Card6-M with deletion of the 281-480 fragment, resulting in the inability to interact with Ask1. We then generated transgenic mice expressing Card6-M specifically in hepatocytes and tested whether the interaction with Ask1 is required for Card6 function in NAFLD in vivo. As expected, WT Card6 efficiently suppressed HFD-induced Ask1 phosphorylation, while Card6-M failed to do so (Fig.  7A) . Accordingly, Card6 overexpression protected Card6-HTG mice from HFD-induced NAFLD as evidenced by improved fasting glucose and insulin and HOMA-IR, GTT, and ITT results and reduced liver weight, lipid accumulation, inflammation, and liver dysfunction (Fig. 7B-K) . In sharp contrast, Card6-M failed to exert a protective effect in HFD-induced NAFLD. Card6-M mice exhibited comparable phenotypes to those of WT mice (Fig. 7B-K) . These observations indicate that the interaction with Ask1 is required for Card6 function in NAFLD.
taRgetINg ask1 By Card6 IS a tHeRapeutIC StRategy FoR NaFlD IN MICe
We used a genetic obesity model (ob/ob mice) to further test whether targeting Ask1 by Card6 resulted in a therapeutic effect in NAFLD. We used an Ad to mediate Card6 overexpression in the liver (Fig. 8A) . Although body weight was not significantly altered by Card6 overexpression in the liver, fasting glucose and insulin were reduced and GTT and ITT results were improved (Fig. 8B-G) . Moreover, AdCard6 overexpression also reduced liver weight and lipid accumulation in livers and decreased inflammatory cytokines/chemokines and liver dysfunction (Fig.  8H-L) . These findings clearly indicate that Card6 can reverse NAFLD progression in genetically obese mice. Targeting Ask1 by Card6 may be a good strategy for NAFLD therapy.
Discussion
NAFLD and NASH are silent diseases that have become one of the most important global health issues. (1, 3) Currently, no effective drugs are available for the treatment of NAFLD and NASH, and only lifestyle changes and weight control can be recommended. (26) Here, we showed that Card6 down-regulation was associated with fatty livers and that Card6 negatively regulated insulin resistance, hepatic steatosis, and the inflammatory response in both dietary and genetic NAFLD. Card6 inhibited p38 and Jnk signaling by suppressing the activation of their upstream kinase Ask1. Furthermore, Card6 function in NAFLD was mainly mediated by Ask1, and the interaction with Ask1 was absolutely required for Card6 function. More importantly, we showed that targeting Ask1 by Card6 results in a therapeutic effect on NAFLD. Our study demonstrates that Card6 may be a promising clinical therapeutic target in the treatment and prevention of hepatic steatosis and insulin resistance and their related diseases.
There exist controversial reports regarding the role of Card6 in NF-κB activation, and the pathophysiological function of Card6 is largely unknown. An early in vitro study showed that Card6 protein suppressed NF-κB activation by nonobese diabetic 1 (Nod1) but did not interfere with NF-κB activation by Bcl10 or Tnf-α. (27) Although Card6 was shown to interact with microtubule and Ripk2 and enhance Nod1-induced NF-κB activation in a second in vitro study, Card6-deficient mice did not exhibit any abnormalities in toll-like receptor and NOD signaling. (12) (13) (14) Therefore, it is important to define the signaling complexes associated with Card6 in order to reveal the pathophysiological function of Card6. Indeed, a recent report showed that Card6 protected against pressure overload-induced cardiac hypertrophy and negatively affected MAPK signaling. (17) In our study, we observed that Card6 down-regulation was tightly associated with NAFLD and that sustained Card6 expression ameliorated NAFLD. Furthermore, Card6 suppressed Jnk, p38, and p65 by interacting and modulating Ask1 in vitro and in vivo. These observations provide evidence that Card6 forms a signaling complex with Ask1 and modulates downstream signaling pathways in NAFLD. Our study strongly suggests that Card6 is an endogenous protective factor in NAFLD.
We identified Card6 as a suppressor of Ask1. As a MAPK kinase kinase, Ask1 selectively activates p38 and JNK. (28) In our study, we demonstrated that the Card6 (281-480) segment interacted with the Ask1 kinase domain and efficiently suppressed Ask1 phosphorylation at the Thr845 site, up-regulating the kinase activity of Ask1 (29, 30) and the activation of downstream p38 and Jnk. Because Card6 is a potential interferon-induced GTPase but not a kinase, it is very interesting to explore how it regulates the activation of Ask1. Multiple mechanisms have been shown to control Ask1 activation, including Ask1 dimerization and interactions with TNF receptor-associated factors and thioredoxin. (31) Whether Card6 affects one of these mechanisms or even an alternative mechanism warrants exploration. Fine mapping or point mutations in the Card6 (281-480) segment may provide more information. Investigating the mechanism of Ask1 phosphorylation inhibition by Card6 may lead to the development of a strategy to generate a Ask1 inhibitor for NAFLD/NASH therapy in the clinical setting.
Our study also indicates that targeting Ask1 by Card6 may be a good strategy for NAFLD/NASH therapy. Ask1 overactivation is highly associated with the progression of NAFLD/NASH. (21) (22) (23) More importantly, Ask1 has been proposed as a target for NASH therapy. Recently, a phase 2 clinical trial to evaluate a selective Ask1 inhibitor, GS-4997, in NASH patients was completed by Gilead Sciences (NCT02466516). GS-4997 selectively inhibits Ask1 by competing with adenosine triphosphate (ATP) in its catalytic kinase domain. (32) However, this traditional strategy was inevitably problematic because all kinases share similarity of ATP-binding pockets. (32, 33) Small peptides based on the specific interaction of Ask1 and Card6 may potentially overcome this defect. One study also showed that a small segment of cellular FLICE-inhibitory protein (c-FLIP) protected against NAFLD/NASH by suppressing Ask1 by disrupting Ask1 dimerization. (23) Our studies indicate that targeting Ask1 using its partners, such as c-FLIP and Card6, may reflect a very effective strategy against NAFLD and NASH. Screening for small peptides or small molecules that can mimic the interactions of Ask1 with its partners, such as c-FLIP and Card6, may be an effective method for developing Ask1 inhibitors for the clinical treatment of NAFLD and NASH.
In summary, our study identified Card6 as a protective factor against NAFLD. Card6 interacted with Ask1 and suppressed its phosphorylation and the activation of downstream p38/Jnk signaling. Targeting Ask1 by Card6 resulted in a therapeutic effect in NAFLD in mice and may be an effective strategy for the development of Ask1 inhibitors for the clinical treatment of NAFLD/NASH.
